Skip to content
10-Q

Quarterly Report

MoonLake Immunotherapeutics MLTX

0001821586-25-000018

← back to feed
Filed
Aug 5, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q2 2025 · Jun 30, 2025 63.28M sh
Shares Diluted Q2 2025 · Jun 30, 2025 63.26M sh
Shares Diluted Q2 2025 · Jun 30, 2024 62.87M sh
Shares Diluted Q2 2025 · Jun 30, 2024 62.76M sh
Capex Q2 2025 · Jun 30, 2025 $35K
Capex restated Q2 2025 · Jun 30, 2024 $212K
Operating Cash Flow Q2 2025 · Jun 30, 2025 −$92.67M
Operating Cash Flow restated Q2 2025 · Jun 30, 2024 −$42.84M
Long Term Debt Q2 2025 · Jun 30, 2025 $73.38M
Long Term Debt Q2 2025 · Dec 31, 2024 $0
Cash And Equivalents Q2 2025 · Jun 30, 2025 $306.68M
Cash And Equivalents Q2 2025 · Dec 31, 2024 $180.43M
Stockholders Equity Q2 2025 · Jun 30, 2025 $353.73M
Stockholders Equity Q2 2025 · Dec 31, 2024 $446.83M
Current Liabilities Q2 2025 · Jun 30, 2025 $27.36M
Current Liabilities Q2 2025 · Dec 31, 2024 $22.46M
Total Liabilities Q2 2025 · Jun 30, 2025 $102.15M
Total Liabilities Q2 2025 · Dec 31, 2024 $24.54M
Current Assets Q2 2025 · Jun 30, 2025 $455.48M
Current Assets Q2 2025 · Dec 31, 2024 $474.29M
Total Assets Q2 2025 · Jun 30, 2025 $460.1M
Total Assets Q2 2025 · Dec 31, 2024 $477.93M
Eps Diluted Q2 2025 · Jun 30, 2025 −$0.87
Eps Diluted Q2 2025 · Jun 30, 2025 −$1.50
Eps Diluted Q2 2025 · Jun 30, 2024 −$0.39
Eps Diluted Q2 2025 · Jun 30, 2024 −$0.60
Eps Basic Q2 2025 · Jun 30, 2025 −$0.87
Eps Basic Q2 2025 · Jun 30, 2025 −$1.50
Eps Basic Q2 2025 · Jun 30, 2024 −$0.39
Eps Basic Q2 2025 · Jun 30, 2024 −$0.60
Sga Expense Q2 2025 · Jun 30, 2025 $10.94M
Sga Expense Q2 2025 · Jun 30, 2025 $21.96M
Sga Expense restated Q2 2025 · Jun 30, 2024 $6.92M
Sga Expense restated Q2 2025 · Jun 30, 2024 $13.72M
Rd Expense Q2 2025 · Jun 30, 2025 $49.76M
Rd Expense Q2 2025 · Jun 30, 2025 $86.22M
Rd Expense restated Q2 2025 · Jun 30, 2024 $23.66M
Rd Expense restated Q2 2025 · Jun 30, 2024 $36.68M
Net Income Q2 2025 · Jun 30, 2025 −$55.22M
Net Income Q2 2025 · Jun 30, 2025 −$95.17M
Net Income restated Q2 2025 · Jun 30, 2024 −$24.27M
Net Income restated Q2 2025 · Jun 30, 2024 −$37.94M
Operating Income Q2 2025 · Jun 30, 2025 −$60.7M
Operating Income Q2 2025 · Jun 30, 2025 −$108.18M
Operating Income restated Q2 2025 · Jun 30, 2024 −$30.58M
Operating Income restated Q2 2025 · Jun 30, 2024 −$50.4M